Page 80 - 2021_12-Haematologica-web

Acute Promyelocytic Leukemia
Ferrata Storti Foundation
Haematologica 2021 Volume 106(12):3100-3106
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide:
an international collaborative study
Sabine Kayser,1,2 Richard F. Schlenk,2,3 Delphine Lebon,4 Martin Carre,5 Katharina S. Götze,6 Friedrich Stölzel,7 Ana Berceanu,8 Kerstin Schäfer-Eckart,9 Pierre Peterlin,10 Yosr Hicheri,11 Ramy Rahmé,12 Emmanuel Raffoux,12 Fatiha Chermat,12 Stefan W. Krause,13 Walter E. Aulitzky,14 Sophie Rigaudeau,15 Richard Noppeney,16 Celine Berthon,17 Martin Görner,18 Edgar Jost,19 Philippe Carassou,20 Ulrich Keller,21 Corentin Orvain,22,23,24 Thorsten Braun,25 Colombe Saillard,26 Ali Arar,27 Volker Kunzmann,28 Mathieu Wemeau,29 Maike de Wit,30 Dirk Niemann,31 Caroline Bonmati,32 Carsten Schwänen,33 Julie Abraham,34 Ahmad Aljijakli,35 Stéphanie Haiat,36 Alwin Krämer,37,38 Albrecht Reichle,39 Martina Gnadler,40 Christophe Willekens,41,42 Karsten Spiekermann,43 Wolfgang Hiddemann,43 Carsten Müller-Tidow,37 Christian Thiede,7 Christoph Röllig,7 Hubert Serve,44 Martin Bornhäuser,7 Claudia D. Baldus,45 Eva Lengfelder,46 Pierre Fenaux,12
Uwe Platzbecker1# and Lionel Adès12#
1Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany; 2NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany 4Service des Maladies du Sang GH Sud, Amiens, France; 5HCE Grenoble, Service d'Oncologie et Hématologie Pédiatrique, Grenoble, France; 6Department of Medicine III, Technical University of Munich, Munich, Germany; 7Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden, TU Dresden, Germany; 8Service d'Hématologie du Pr. Cahn Hopital Jean Minjoz, Besancon, France; 9Hospital Nord, Nurnberg, Germany; 10Service d'Hématologie, Hotel Dieu Nantes, France; 11Département d'Hématologie Clinique du Chu Saint Eloi Montpellier, Montpellier, France; 12Hôpital Saint Louis, Université Paris Diderot, Paris, France; 13Department of Internal Medicine 5 – Hematology/Oncology, University Hospital of Erlangen, Erlangen, Germany; 14Robert-Bosch-Hospital, Stuttgart, Germany; 15Service d'Hémato-Oncologie du Pr. Castaigne Hopital Andre Mignot le Chesnay, Versailles, France; 16University Hospital Essen, Essen, Germany; 17Service des Maladies du Sang Chru, Hopital Claude Huriez, Lille, France; 18Klinik für Hämatologie, Onkologie und Palliativmedizin, Klinikum Bielefeld Mitte, Bielefeld, Germany; 19University Hospital Aachen, Aachen, Germany; 20Department of Hematology, Centre Hospitalier Régional (CHR) Metz-Thionville, Metz, France; 21Department of Hematology, Oncology and Tumor Immunology, Charité-University Medical Center, Campus Benjamin Franklin, Berlin, Germany; 22Angers University Hospital, Maladies du Sang, Angers, France; 23Fédération Hospitalo-Universitaire Grand-Ouest Acute Leukemia, FHU-GOAL, France; 24Université d'Angers, INSERM, CRCINA, Angers, France; 25Hôpital Avicenne, Assistance Publique - Hôpitaux de Paris, Université Paris 13, Bobigny, France; 26Hematology Department, Institut Paoli Calmettes, Marseille, France; 27Service d' Oncologie Médicale Hopital de la Source, Orleans, France; 28University Hospital of Würzburg, Würzburg, Germany; 29Service d'Hématologie, Hopital V. Provo, Roubaix, France; 30Vivantes Klinikum Neukölln, Berlin, Germany; 31Gemeinschaftsklinikum Mittelrhein gGmbH, Koblenz, Germany; 32Division of Hematology, Hôpital de Brabois, Centre Hospitalier Universitaire de Nancy, Nancy, France; 33Klinikum Offenburg, Offenburg, Germany; 34Service d' Hématologie, Thérapie Cellulaire du Pr. Bordessoule, Hopital Universitaire Dupuytren, Limoges, France; 35Service d'Hématologie du Dr. Sutton Centre Hospitalier v. Dupouy, Argenteuil, France; 36Service d'Hematologie Clinique, CH Sud Francilien, Corbeil Essonnes, France; 37Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany; 38German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; 39Department of Medicine III - Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany; 40St. Vincentius Kliniken, Abteilung für Hämatologie, Onkologie, Immunologie und Palliativmedizin, Karlsruhe, Germany; 41Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France; 42INSERM Unit 1287, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France; 43Department of Medicine III, University Hospital, Ludwig-Maximilians University (LMU) Munich, Munich, Germany; 44Department of Internal Medicine II, University Hospital of Frankfurt am Main, Germany; 45Department of Internal Medicine II, University Hospital of Kiel, Kiel, Germany and 46Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
#UP and LA contributed equally as co-senior authors.
Presented in part at the 21st Annual Meeting of the European Hematology Association in Frankfurt, Germany, June 10th, 2020.
Correspondence:
SABINE KAYSER
sabine.kayser@medizin.uni-leipzig.de
Received: March 6, 2021. Accepted: April 26, 2021. Pre-published: May 27, 2021.
https://doi.org/10.3324/haematol.2021.278722 ©2021 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or inter- nal use. Sharing published material for non-commercial pur- poses is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for com- mercial purposes is not allowed without permission in writing from the publisher.
3100
haematologica | 2021; 106(12)
ARTICLE